Innovent Biologics' (HKG:1801) Sintbilo and Olverembatinib have been included in China's National Reimbursement Drug List, officially effective Jan. 1, 2025, a Thursday bourse filing said.
Sintbilo has been newly listed for the treatment of adult patients with primary hypercholesterolemia and mixed dyslipidemia.
The first indication of olverembatinib was renewed while a new indiation was also included in the list. The drug is now included in the list for the treatment of adult patients with chronic- or accelerated-phase chronic myeloid leukemia.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments